Edwards Lifesciences (EW) Cvp, Tavr Lippis Sells 619 Shares

Lippis Sells Shares of Edwards Lifesciences

Daniel Lippis, a corporate vice president at Edwards Lifesciences Corporation (NYSE: EW), sold 619 shares on June 30, 2026. The shares were valued around $55,935 based on a trading price of $90.46 at the time of writing.

What Changed?

This sale adds to a recent pattern of insider trading at Edwards Lifesciences. Lippis sold the shares but did not disclose any specific reason for the transaction. His move contrasts with the company's performance, with shares currently trading close to their year-high of $96.29.

Insider Buying and Selling at Edwards Lifesciences Corporation

In addition to Lippis's recent sale, CEO Bernard Zovighian also sold shares on June 17, 2026. Zovighian liquidated 523 shares, valued at about $45,982, at an average price of $87.92. This planned sale reflects ongoing insider activity within the company, though it's important to note that selling shares does not necessarily indicate negative sentiment.

How Edwards Lifesciences Corporation Stock Has Traded

Edwards Lifesciences shares are trading around $90.46, which is just above their previous close of $88.26. The stock has been fluctuating in the range of its 52-week low of $72.30 and high of $96.29. With the stock near its highs, these insider transactions may draw attention as investors consider company stability and future growth potential.

Analysts Set New Price Targets

Analysts have shown a generally positive outlook on Edwards Lifesciences. On October 7, 2026, Barclays initiated coverage with an Overweight rating and a price target of $110.00. Recently, firms such as BTIG and JP Morgan have also reiterated their Buy and Overweight ratings, respectively, with targets ranging from $95.00 to $110.00. This positive sentiment suggests that analysts believe in the company's future profitability despite recent insider selling.

What Edwards Lifesciences Corporation Does

Edwards Lifesciences Corporation specializes in products and technologies for treating advanced cardiovascular diseases. Its offerings include transcatheter heart valve replacement products and various surgical structural heart solutions. The recent insider transactions might influence perceptions as the company continues to innovate in the medical devices sector.

What’s Next?

Investors will be watching for the next earnings report on October 29, 2026, to assess the company's financial health. As a reminder, the recent insider transactions reflect past decisions and may not represent current positions. Further filings and any new insider trades could provide additional insights into the company's direction.